Search

Displaying results 2281 - 2290 of 2959 in total
  1. Drug

    Cefdinir

    go.drugbank.com/drugs/DB00535
    ApprovedInvestigational

    Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.

    International brands: Xi Fu Ni
  2. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542]

  3. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    [A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]

  4. Drug

    Taurolidine

    go.drugbank.com/drugs/DB12473
    ApprovedInvestigational

    [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial

  5. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]

  6. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    A letter of non-approval for parecoxib was issued by the FDA in 2005.

  7. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  8. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  9. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  10. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.